Abstract:Bioactive glass nanoparticles (BGN) have attracted increasing attention for their use in bone tissue repair owing to their special osteogenic activity; however, the underlying molecular mechanism remains unclear. In this study, we report a new mechanism by which BGN regulate bone loss in an osteoporosis mouse model. We found that BGN induced the expression of extracellular vesicles secreted by bone marrow mesenchymal stem cells (BGN + BMSC-EVs), which can inhibit osteoclast differentiation in vitro. Furthermore, our results showed that BGN + BMSC-EVs were rich in the long non-coding RNA NRON, which can inhibit the nuclear translocation of NFATc1 by binding to the nuclear factor of activated T cells transcription factors, thereby inhibiting osteoclast differentiation. We validated the function and biological safety of BGN + BMSC-EVs in an ovariectomized mouse model of osteoporosis. The results of in vivo studies showed that BGN + BMSC-EVs could alleviate bone loss in osteoporotic mice, restore the mechanical properties of mouse femurs, and improve the biochemical indicators in the peripheral blood for bone metabolism in mice, with little to no acute, systemic toxicity. This study may provide a new explanation for the role of BGN in inhibiting osteoclast differentiation and relieving bone loss; additionally, the study findings reveal a promising strategy for the treatment of bone resorption disorders.

Bioactive glass nanoparticles inhibit osteoclast differentiation and osteoporotic bone loss by activating lncRNA NRON expression in the extracellular vesicles derived from bone marrow mesenchymal stem cells